TNFRSF17 and Miyoshi myopathy: Regarding hematological cancers, lineage markers such as CD19 for B cell lymphoma [8,9,10] or BCMA for multiple myeloma (MM) [11,38,39] can be targeted at the expense of also eliminating the respective healthy cell population.